arrow
S

Scott J. Diede

Merck & Co. Inc.
H指数:30
被引数:6,526

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma

随机、双盲、III期LEAP-003研究:比较一线仑伐替尼联合帕博利珠单抗与安慰剂联合帕博利珠单抗治疗不可切除或转移性黑色素瘤的疗效。

2025-08-280
PREAI
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
2021-11-0118
OAAI
MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)

MASTERKEY-265: talimogene laherparepvec (T) 联合pembrolizumab (P) 治疗不可切除期IIIB-IVM1c黑色素瘤 (MEL) 的III期随机安慰剂 (Pbo) 对照研究

2021-09-0133
OAAI
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

派姆单抗单药治疗的长期安全性及其与临床结果的关系: 晚期黑色素瘤患者的里程碑分析

2021-02-0166
OAAI
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
2020-03-0150
OAAI
5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma
2019-07-014
PRE